TABLE 3.

Other Benefits or Disadvantages

In the treatment of patients aged ≥ 12 years with moderate to severe asthma, does dupilumab offer 1 or more of the following potential other benefits or disadvantages compared with standard of care without biologic treatment?
Potential Benefit	Panel Votesa
Dupilumab offers reduced complexity that will significantly improve patient outcomes	3
Dupilumab will reduce important health disparities across racial, ethnic, gender, socioeconomic, or regional categories	0
Dupilumab will significantly reduce caregiver or broader family burden	6
Dupilumab offers a novel mechanism of action or approach that will allow successful treatment of many patients who have failed other treatments	8
Dupilumab will have a significant impact on improving patients’ ability to return to work and/or their overall productivity	7
There are other important benefits or disadvantages that should have an important role in judgements of the value of this intervention	3

^aFifteen panelists voted.